EEF1A1 and metabolic dysfunction-associated steatotic liver disease: Future investigations in animal models of progressive NAFLD and liver fibrosis, and in the cell types involved in hepatic inflammation and fibrosis, will be critical for determining whether didemnin B, or inhibition of EEF1A1, will be effective in later stages of this disease.